Surfactant-based drug delivery systems for treating drug-resistant lung cancer

Table 2. Commercially available hydrophobic and hydrophilic surfactants (Griffin, Citation1955).

Figure 4. Structural characteristics of novel surfactants.

Table 3. Common uses of surfactant categories with their features (Dickinson, Citation1992; Solans & Kunieda, Citation1996).

Figure 5. Pharmaceutical excipients as P-gp inhibitors.

Figure 6. Mechanism undertaken for P-glycoprotein-mediated efflux for excipients (Bansal et al., Citation2009).

Table 4. Advanced formulations on the basis of P-gp modulation.

Griffin WC. (1955). Calculation of HLB values of non-ionic surfactants. Am Perfumer Essent Oil Rev 65:26–9

Dickinson, E. (1992). Introduction to food colloids. Oxford, UK: Oxford University Press

Solans C, Kunieda, H. (1996). Industrial applications of microemulsions. New York, USA: Marcel Dekker

Bansal T, Jaggi M, Khar R, Talegaonkar S. (2009). Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12:46–78

Föger F, Schmitz T, Bernkop-Schnürch, A. (2006). In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27:4250–5

Wu J, Lu Y, Lee A, et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10:350–7

Emilienne Soma C, Dubernet C, Bentolila D, et al. (2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1–7

Xiao Yan L, McTan T, Lee H. (2005). In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28:822–8

Dabholkar RD, Sawant RM, Mongayt DA, et al. (2006). Polyethylene glycol–phosphatidylethanolamine conjugate (PEG–PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 315:148–57

Chavanpatil MD, Patil Y, Panyam J. (2006). Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 320:150–6

Wong HL, Bendayan R, Rauth AM, Wu XY. (2006). Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Rel 116:275–84

Št’astný M, Strohalm J, Plocova D, et al. (1999). A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 35:459–66

Lamprecht A, Benoit J-P. (2006). Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Rel 112:208–13

Du J, Lu W-L, Ying X, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood−brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6:905–17

Koziara JM, Whisman TR, Tseng MT, Mumper RJ. (2006). In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Rel 112:312–19

Patil Y, Sadhukha T, Ma L, Panyam, J. (2009). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Rel 136:21–9

Yang S, Gursoy RN, Lambert G, Benita, S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261–70

Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37:300–5

Patel NR, Rathi A, Mongayt D, Torchilin VP. (2011). Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 416:296–9

Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. (2005). Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Rel 107:143–57

Zhang Z, Feng S-S. (2006a). The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27:4025–33

Zhang Z, Feng S-S. (2006b). Self-assembled nanoparticles of poly (lactide)–vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324:191–8

Iffert T, Soldan M, Moeller A, Maser, E. (2000). Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology 144:189–95

Elkharraz K, Faisant N, Guse C, et al. (2006). Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 314:127–36

Št’astný M, Plocová D, Etrych T, et al. (2002). HPMA-hydrogels containing cytostatic drugs: kinetics of the drug release and in vivo efficacy. J Control Rel 81:101–11

Guillemard V, Saragovi HU. (2004). Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23:3613–21

Ho EA, Soo PL, Allen C, Piquette-Miller, M. (2007). Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Rel 117:20–7